The Future of Presbyopia Drops - Takeaways - MDSpire

The Future of Presbyopia Drops

An update on the expanding category of topical drugs to treat presbyopia.

  • By

  • Jennifer Ponte Canning, Managing Editor

  • April 1, 2025

  • 8 min

Share

  • 1

    Vuity is the first FDA-approved eye drop for presbyopia, enhancing near vision without significantly affecting distance vision.

  • 2

    Qlosi, approved in 2023, offers a lower dose of pilocarpine and similar benefits to Vuity, but is not yet commercially available.

  • 3

    LNZ100, a new pupil-selective miotic, has shown promise in phase 3 trials and aims for FDA approval by August 2025.

  • 4

    Brimochol PF combines carbachol and brimonidine to improve near vision with fewer side effects, targeting a 2026 launch.

  • 5

    Ryzumvi, initially approved for mydriasis reversal, is under investigation for presbyopia treatment in ongoing phase 3 trials.

Original Source(s)

The Future of Presbyopia Drops

  • by Jennifer Ponte Canning, Managing Editor

  • April 1, 2025

Related Content

Outcomes of Vision with a Diffractive Trifocal Intraocular Lens in Patients with Short Axial Length

Cataract Surgeons Gain a New Lens Tool

An extended depth of focus intraocular lens approved by the FDA is designed to improve visual range while maintaining contrast sensitivity in cataract surgery.

Therapeutic Focus: <em>Drop</em>ping Some Knowledge

Vizz (aceclidine ophthalmic solution) 1.44%, from Lenz Therapeutics, offers spectacle-free vision and the opportunity to secure patient loyalty.